A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor	Active, not recruiting	Phase 1 / Phase 2	2026-09-11		NCT04201457

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
American Lebanese Syrian Associated Charities	1
National Cancer Institute (NCI)	3015
Pediatric Brain Tumor Consortium	2

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Healthcare of Atlanta	Atlanta	United States	47
Children's Hospital Colorado	Aurora	United States	312
Children's Hospital Los Angeles	Los Angeles	United States	4
Children's Hospital of Pittsburgh	Pittsburgh	United States	16
Children's National Medical Center	Washington D.C.	United States	3
Cincinnati Children Hospital Medical Center	Cincinnati	United States	1
Lucile Packard Children's Hospital at Stanford University Medical Center	Palo Alto	United States	4
Lurie Children's Hospital-Chicago	Chicago	United States	1
Memorial Sloan Kettering Cancer Center	New York	United States	1000
National Cancer Institute Pediatric Oncology Branch	Bethesda	United States	1
Nationwide Children's Hospital	Columbus	United States	309
Phoenix Children's Hospital	Phoenix	United States	95
St. Jude Children Research Hospital	Memphis	United States	1
Texas Children's Cancer Center	Houston	United States	4
University of Florida	Gainesville	United States	70